Viewing Study NCT02187302


Ignite Creation Date: 2025-12-25 @ 3:48 AM
Ignite Modification Date: 2026-03-28 @ 1:09 AM
Study NCT ID: NCT02187302
Status: COMPLETED
Last Update Posted: 2020-05-28
First Post: 2014-06-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Sponsor: NewLink Genetics Corporation
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module